Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.35 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392621 | 1.00 | GPR119 (0.47) | GPR119KCNH2GPR183RAB9AHPGDS | |
| SCHEMBL1838268 | 0.95 | GPR119 (0.48) | GPR119KCNH2GPR183RAB9AABL1 | |
| SCHEMBL2398398 | 0.95 | GPR119 (0.48) | GPR119KCNH2GPR183ABL1BMPR1B | |
| SCHEMBL2397233 | 0.92 | GPR119 (0.51) | GPR119KCNH2GPR183RAB9A | |
| SCHEMBL2397230 | 0.92 | GPR119 (0.51) | GPR119KCNH2GPR183RAB9A | |
| SCHEMBL2395228 | 0.89 | GPR119 (0.42) | GPR119RAB9AHPGDSEGLN1ABL1 | |
| SCHEMBL2215219 | 0.89 | GPR119 (0.42) | GPR119RAB9AHPGDSEGLN1ABL1 | |
| SCHEMBL2215217 | 0.89 | GPR119 (0.42) | GPR119RAB9AHPGDSEGLN1ABL1 | |
| SCHEMBL2398405 | 0.89 | GPR119 (0.42) | GPR119RAB9AHPGDSEGLN1ABL1 | |
| SCHEMBL2394392 | 0.89 | GPR119 (0.42) | GPR119RAB9AHPGDSEGLN1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | claimed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | claimed |
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230507-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | GPR119 1/4885KCNH2 1120/4885GPR183 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.